No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
LTH240517C15000
- 0.30
- +0.05+20.00%
15min DelayClose May 9 16:00 ET
0.30High0.20Low
0.20Open0.25Pre Close6 Volume374 Open Interest15.00Strike Price170.00Turnover42.34%IV3.10%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier7DDays to Expiry0.30Time Value100Contract SizeAmericanOptions Type0.4503Delta0.4320Gamma49.47Leverage Ratio-0.0251Theta0.0014Rho22.28Eff Leverage0.0086Vega
Intraday
- 5D
- 1D
News
Life Time Group Holdings First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Planet Fitness Is Raising Prices Even as It Warns Customers Are Growing Cost-conscious
Planet Fitness is hiking its base-level membership prices for new customers for the first time since 1998, even as the gym operator warns its customers are growing increasingly cost-conscious. The company reported weaker-than-expected first-quarter revenue and cut guidance for the fiscal year. Interim CEO Craig Benson said several macro conditions weighed on an increasingly price-sensitive consumer.
FITAID of LIFEAID Beverage Co. LLC, Releases Two New Flavors of FITAID RX Zero, Only One Will Stay
Life Time | 10-Q: Quarterly report
Express News | Life Time and Lululemon Announce New Partnership
Life Time Fitness Leans Into Pickleball With Lululemon Partnership, New Courts and More
Life Time fitness is all in on pickleball.
Comments
The stock appears overpriced with its high beta causing amplified price movements. Its optimistic future growth seems already factored into the current share price, making it potentially not the best time to buy as it has outpaced its industry peers.
Is There Now An Opportunity In Life Time Group Holdings, Inc. (NYSE:LTH)? 1
Despite lower forecasted growth, Life Time Group's P/S ratio is on par with industry peers, hinting investor loyalty. However, alignment of P/S ratio with the growth outlook could result in disappointment. Weak revenue outlook puts the share price at risk requiring positive change to justify P/S ratio.
$Life Time(LTH.US$ another good earnings yet they dumped it. Trash market.
Gapping up
Select biotech/pharma names showing strength following ESMO:
$Clovis Oncology(CLVS.US$ +11.3%, $Cardiff Oncology(CRDF.US$ +9%, $Immatics(IMTX.US$ +8.3%, $IDEAYA Biosciences(IDYA.US$ +8%, $Lyra Therapeutics(LYRA.US$ +5.7%, $POINT Biopharma(PNT.US$ +5.7%, $Edgewise Therapeutics(EWTX.US$ +4.7%, $Concert Pharmaceuticals(CNCE.US$ +3.6%, $Deciphera Pharmaceuticals(DCPH.US$ +3.2%, $Veracyte(VCYT.US$ +2.6%, $SpringWorks Therapeutics(SWTX.US$ +2.3%,...
Select biotech/pharma names showing strength following ESMO:
$Clovis Oncology(CLVS.US$ +11.3%, $Cardiff Oncology(CRDF.US$ +9%, $Immatics(IMTX.US$ +8.3%, $IDEAYA Biosciences(IDYA.US$ +8%, $Lyra Therapeutics(LYRA.US$ +5.7%, $POINT Biopharma(PNT.US$ +5.7%, $Edgewise Therapeutics(EWTX.US$ +4.7%, $Concert Pharmaceuticals(CNCE.US$ +3.6%, $Deciphera Pharmaceuticals(DCPH.US$ +3.2%, $Veracyte(VCYT.US$ +2.6%, $SpringWorks Therapeutics(SWTX.US$ +2.3%,...
10
$Life Time(LTH.US$ New trend line confirmed? Higher lows with 3 touch points now on the 5 min chart
Read more